VolitionRX (NYSEAMERICAN:VNRX) Given “Hold” Rating at D. Boral Capital

VolitionRX (NYSEAMERICAN:VNRX)‘s stock had its “hold” rating reaffirmed by D. Boral Capital in a note issued to investors on Monday,Benzinga reports.

A number of other equities analysts have also recently issued reports on the company. HC Wainwright cut their price target on VolitionRX from $1.50 to $1.00 and set a “buy” rating on the stock in a report on Thursday, April 2nd. Citigroup lowered VolitionRX to a “hold” rating in a research report on Monday. One analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat.com, VolitionRX currently has a consensus rating of “Moderate Buy” and an average target price of $2.33.

VolitionRX Stock Performance

VolitionRX stock opened at $0.18 on Monday. The stock has a market capitalization of $28.34 million, a price-to-earnings ratio of -0.81 and a beta of 1.33. VolitionRX has a 52-week low of $0.15 and a 52-week high of $0.94. The stock’s 50 day moving average price is $0.20 and its two-hundred day moving average price is $0.29.

VolitionRX (NYSEAMERICAN:VNRX) last posted its quarterly earnings results on Tuesday, March 31st. The medical research company reported ($0.05) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.05). The business had revenue of $0.45 million for the quarter, compared to the consensus estimate of $0.71 million. On average, equities research analysts forecast that VolitionRX will post -0.5 EPS for the current year.

Institutional Investors Weigh In On VolitionRX

Institutional investors and hedge funds have recently bought and sold shares of the stock. Jane Street Group LLC bought a new position in VolitionRX during the 4th quarter valued at $28,000. Virtu Financial LLC lifted its stake in VolitionRX by 166.6% during the 4th quarter. Virtu Financial LLC now owns 108,581 shares of the medical research company’s stock valued at $28,000 after acquiring an additional 67,848 shares in the last quarter. Squarepoint Ops LLC bought a new position in VolitionRX during the 4th quarter valued at $34,000. Northwestern Mutual Wealth Management Co. bought a new position in VolitionRX during the 2nd quarter valued at $52,000. Finally, Citadel Advisors LLC lifted its stake in VolitionRX by 70.1% during the 3rd quarter. Citadel Advisors LLC now owns 329,520 shares of the medical research company’s stock valued at $224,000 after acquiring an additional 135,775 shares in the last quarter. 8.09% of the stock is owned by hedge funds and other institutional investors.

About VolitionRX

VolitionRX, traded as VNRX on the NYSE American exchange, is a pioneering life sciences company focused on the development and commercialization of minimally invasive diagnostic tests for the early detection of cancer and other diseases. Utilizing proprietary technology to analyze circulating nucleosomes in blood samples, the company’s platform identifies disease-specific epigenetic and biochemical signatures. By offering blood-based screening solutions, VolitionRX aims to deliver alternatives to invasive, costly and time-consuming procedures, potentially improving patient outcomes through earlier diagnosis.

The company’s flagship product suite, branded as Nu.Q, comprises assays designed to detect biomarkers associated with a range of malignancies, including colorectal, lung and pancreatic cancers, as well as other systemic conditions.